• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Dynamics Special Purpose Corp.

    7/15/22 5:24:53 PM ET
    $DYNS
    Get the next $DYNS alert in real time by email
    SC 13D 1 nea15_18630.htm NEW ENTERPRISE ASSOCIATES 15, L.P. / SENTI BIOSCIENCES, INC. -- SCHEDULE 13D Schedule 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No.   )*

     

     

    Senti Biosciences, Inc.

    (Name of Issuer)

    Common Stock, $.0001 par value

    (Title of Class of Securities)

    81726A100

    (CUSIP Number)

    Louis S. Citron, Esq.

    New Enterprise Associates

    1954 Greenspring Drive, Suite 600, Timonium, MD 21093

    (410) 842-4000

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

    June 8, 2022

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 81726A100

    13D Page 2 of 18 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    New Enterprise Associates 15, L.P.

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    WC

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware Limited Partnership

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    4,426,151 shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    4,426,151 shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,426,151 shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    10.1%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    PN

     

       

     

     

     

    CUSIP No. 81726A100

    13D Page 3 of 18 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    NEA Partners 15, L.P.

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware Limited Partnership

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    4,426,151 shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    4,426,151 shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,426,151 shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    10.1%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    PN

     

       

      

     

     

     

     CUSIP No. 81726A100

    13D Page 4 of 18 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    NEA 15 GP, LLC

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware Limited Liability Company

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    4,426,151 shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    4,426,151 shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,426,151 shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    10.1%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    OO

     

       

     

     

     

      CUSIP No. 81726A100

    13D Page 5 of 18 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Forest Baskett

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 shares

     

      8.  

    SHARED VOTING POWER

     

    4,426,151 shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    4,426,151 shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,426,151 shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    10.1%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

     

     

    CUSIP No. 81726A100

    13D Page 6 of 18 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Anthony A. Florence, Jr.

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    4,426,151 shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    4,426,151 shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,426,151 shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    10.1%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

     

     

    CUSIP No. 81726A100

    13D Page 7 of 18 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Mohamad H. Makhzoumi

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    4,426,151 shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

        4,426,151 shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

        4,426,151 shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    10.1%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

     

    CUSIP No. 81726A100

    13D Page 8 of 18 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Scott D. Sandell

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 shares

     

      8.  

    SHARED VOTING POWER

     

    4,426,151 shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    4,426,151 shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,426,151 shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    10.1%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

     

    CUSIP No. 81726A100

    13D Page 9 of 18 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Peter W. Sonsini

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 shares

     

      8.  

    SHARED VOTING POWER

     

    4,426,151 shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    4,426,151 shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,426,151 shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    10.1%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

     

    CUSIP No. 81726A100

    13D Page 10 of 18 Pages    

    Item 1.  Security and Issuer.

    This Schedule 13D relates to the common stock, $.0001 par value (the “Common Stock”) of Senti Biosciences, Inc. (the “Issuer”) having its principal executive office at 2 Corporate Drive, First Floor, South San Francisco, CA 94080.

     

    Item 2.  Identity and Background.

    This statement is being filed by:

     

    (a) New Enterprise Associates 15, L.P. (“NEA 15”), NEA Partners 15, L.P. (“NEA Partners 15”), which is the sole general partner of NEA 15; and NEA 15 GP, LLC (“NEA 15 LLC” and, together with NEA Partners 15, the “Control Entities”), which is the sole general partner of NEA Partners 15; and

     

    (b) Forest Baskett (“Baskett”), Anthony A. Florence, Jr. (“Florence”), Mohamad H. Makhzoumi (“Makhzoumi”), Scott D. Sandell (“Sandell”) and Peter W. Sonsini (“Sonsini”) (together, the “Managers”). The Managers are the managers of NEA 15 LLC.

     

    The persons named in this Item 2 are referred to individually herein as a “Reporting Person” and collectively as the “Reporting Persons.”

     

    The address of the principal business office of each Control Entity and Sandell is New Enterprise Associates, 1954 Greenspring Drive, Suite 600, Timonium, MD 21093. The address of the principal business office of Baskett, Makhzoumi and Sonsini is New Enterprise Associates, 2855 Sand Hill Road, Menlo Park, California 94025. The address of the principal business office of Florence is New Enterprise Associates, 104 Fifth Avenue, 19th Floor, New York, NY 10011.

     

    The principal business of NEA 15 is to invest in and assist growth-oriented businesses located principally in the United States. The principal business of NEA Partners 15 is to act as the sole general partner of NEA 15. The principal business of NEA 15 LLC is to act as the sole general partner of NEA Partners 15. The principal business of each of the Managers is to manage the Control Entities and a number of affiliated partnerships with similar businesses.

     

    During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding or has been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    NEA 15 LLC is a limited liability company organized under the laws of the State of Delaware. NEA 15 and NEA Partners 15 are limited partnerships organized under the laws of the State of Delaware. Each of the Managers is a United States citizen.

     

     

    Item 3.  Source and Amount of Funds or Other Consideration.

    On June 8, 2022, Dynamics Special Purpose Corp., a Delaware corporation (“DYNS”), consummated a business combination pursuant to the terms of the business combination agreement, dated December 19, 2021 and amended on February 12, 2022 and May 19, 2022 (as amended, the “Business Combination Agreement”) as further described in the Issuer’s Form 8-K Filed with the Securities and Exchange Commission (“SEC”) on May 24, 2022, the descriptions of which are incorporated by reference herein, with Explore Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of DYNS (“Merger Sub”), and Senti Biosciences, Inc., a Delaware corporation (“Senti”). Pursuant to the terms of the Business Combination Agreement, Merger Sub merged with and into Senti, with Senti surviving the merger as a wholly-owned subsidiary of DYNS (the “Business Combination”). In connection with the consummation of the Business Combination, DYNS changed its corporate name to Senti Biosciences, Inc. (the “Issuer”).

     

     

     

     

     

     

    CUSIP No. 81726A100

    13D Page 11 of 18 Pages    

     

     

     

    Prior to the Business Combination, the NEA 15 acquired (i) 13,486,765 shares of Senti Series A Redeemable Convertible Preferred Stock (the “Series A Preferred”) through the payment of cash proceeds and the conversion of a convertible promissory note issued in 2016 (the “2016 Promissory Note”), and (ii) 2,742,931 shares of Series B Redeemable Convertible Preferred Stock (the “Series B Preferred”) through the conversion of a convertible promissory note issued in 2020 (the “2020 Note”) for an aggregate purchase price of $25,148,000. On June 8, 2022, all shares of Series A Preferred and Series B Preferred were cancelled and converted into the right to receive a number of shares of Common Stock, rounded down to the nearest whole share, equal to the aggregate number of shares of Common Stock issuable upon conversion of the shares of Series A and B Preferred based on the applicable conversion ratio immediately prior to the effective time of the Business Combination, which was 1:1, multiplied by an exchange ratio of 0.1957. Post conversion (i) NEA 15 held a total of 3,176,151 shares of Common Stock with 2,639,360 shares issued and converted from Series A Preferred and 536,791 from Series B.

    On June 8, 2022, NEA 15 acquired an additional 1,250,000 shares of Common Stock pursuant to a separate subscription agreement (the “Subscription Agreement”) in a private transaction, for a purchase price of $10.00 per share. NEA 15 now holds a total of 4,426,151 shares of Common Stock (the “NEA 15 Shares”), including the (x) 1,250,000 acquired pursuant to the Subscription Agreement plus (y) 3,176,151 resulting from the conversion of the Series A and B Preferred.

     

    Item 4.  Purpose of Transaction.

    NEA 15 acquired the NEA 15 Shares for investment purposes. Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, NEA 15 and other Reporting Persons may dispose of or acquire additional shares of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in:

     

    (a)The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer;

     

    (b)An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries;

     

    (c)A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries;

     

    (d)Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;

     

    (e)Any material change in the present capitalization or dividend policy of the Issuer;

     

    (f)Any other material change in the Issuer’s business or corporate structure;

     

    (g)Changes in the Issuer’s charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person;

     

    (h)Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;

     

    (i)A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934; or

     

    (j)Any action similar to any of those enumerated above.

     

     

     

     

     

     

    CUSIP No. 81726A100

    13D Page 12 of 18 Pages    

     

     

    Item 5.  Interest in Securities of the Issuer.

    (a)NEA 15 is the record owner of the NEA 15 Shares. As the general partner of NEA 15, NEA Partners 15 may be deemed to own beneficially the NEA 15 Shares. As the sole general partner of NEA Partners 15, NEA 15 LLC may be deemed to own beneficially the NEA 15 Shares. As members of NEA 15 LLC, each of the Managers may be deemed to own beneficially the NEA 15 Shares.

     

    Each Reporting Person disclaims beneficial ownership of the NEA 15 Shares, other than those shares which such person owns of record.

     

    The percentage of outstanding Common Stock of the Issuer which may be deemed to be beneficially owned by each Reporting Person is set forth on Line 13 of such Reporting Person’s cover sheet. Such percentage was calculated based on 43,657,077 shares of Common Stock reported by the Issuer to be outstanding on its Registration Statement on the Form S-1 filed with the SEC on June 28, 2022 (the “Form S-1”).

     

    (b)Regarding the number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote: See line 7 of cover sheets

     

    (ii)shared power to vote or to direct the vote: See line 8 of cover sheets

     

    (iii)sole power to dispose or to direct the disposition: See line 9 of cover sheets

     

    (iv)shared power to dispose or to direct the disposition: See line 10 of cover sheets

     

    (c)Except as set forth in Item 3 above, none of the Reporting Persons has effected any transaction in the NEA 15 Shares during the last 60 days.

     

    (d)No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, NEA 15 Shares beneficially owned by any of the Reporting Persons.

      

     

     

    Item 6.  Contracts, Arrangements, Undertakings or Relationships with Respect to Securities of the Issuer.

    Pursuant to the Business Combination Agreement, 137,271 additional shares of Common Stock will vest for NEA 15 contingent on the occurrence of each event, and for the avoidance of doubt only once upon the occurrence of each of (i) and (ii), as follows: (i) if at any time during the 24 months following the effective date of the Business Combination the volume weighted average price of shares of the Common Stock (the "VWAP") is greater than or equal to $15.00 over any 20 trading days within any consecutive 30 trading day period and (ii) if at any time during the 36 months following the Effective Date the VWAP is greater than or equal to $20.00 over any 20 trading days within any consecutive 30 trading day period.

    NEA 15 entered into the Purchase Agreement as further described in the Form S-1, the description of which is incorporated by reference herein. 

     

    Item 7.  Material to Be Filed as Exhibits.

    Exhibit 1 – Agreement regarding filing of joint Schedule 13D.

     

    Exhibit 2 – Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended.

     

     

     

     

     

     

    CUSIP No. 81726A100

    13D Page 13 of 18 Pages    

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    EXECUTED this 15th day of July, 2022.

     

     

    NEW ENTERPRISE ASSOCIATES 15, L.P.

     

    By:

    NEA PARTNERS 15, L.P.

    General Partner

     

    By:

    NEA 15 GP, LLC

    General Partner

      

      By:          *                                

     Louis S. Citron

     Chief Legal Officer 

     

    NEA PARTNERS 15, L.P.

     

    By:NEA 15 GP, LLC
    General Partner

     

    By:          *                                

    Louis S. Citron

    Chief Legal Officer 

     

      

    NEA 15 GP, LLC

     

    By:          *                                

    Louis S. Citron

    Chief Legal Officer

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    CUSIP No. 81726A100

    13D Page 14 of 18 Pages    

     

     

     

     

                     *                        

    Forest Baskett

     

     

                     *                        

    Anthony A. Florence, Jr.

     

     

                     *                        

    Mohamad H. Makhzoumi

     

     

                     *                        

    Scott D. Sandell

     

     

                     *                        

    Peter W. Sonsini

     

     

     

     

     

     

     

    */s/ Louis S. Citron           

    Louis S. Citron

    As attorney-in-fact

     

     

    This Schedule 13D was executed by Louis S. Citron on behalf of the individuals listed above pursuant to a Power of Attorney a copy of which is attached as Exhibit 2.

     

     

     

     

     

     

     

     

     

     
     

     

    CUSIP No. 81726A100

    13D Page 15 of 18 Pages    

     

    EXHIBIT 1

     

    AGREEMENT

     

    Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of stock of Senti Biosciences, Inc.

     

    EXECUTED this 15th day of July, 2022.

     

     

    NEW ENTERPRISE ASSOCIATES 15, L.P.

     

    By:

    NEA PARTNERS 15, L.P.

    General Partner

     

    By:

    NEA 15 GP, LLC

    General Partner

      

      By:          *                                

    Louis S. Citron

    Chief Legal Officer

     

    NEA PARTNERS 15, L.P.

     

    By:NEA 15 GP, LLC
    General Partner

     

    By:          *                                

    Louis S. Citron

    Chief Legal Officer

     

      

    NEA 15 GP, LLC

     

    By:          *                                

    Louis S. Citron

    Chief Legal Officer

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    CUSIP No. 81726A100

    13D Page 16 of 18 Pages    

     

     

     

     

     

                     *                        

    Forest Baskett

     

     

                     *                        

    Anthony A. Florence, Jr.

     

     

                     *                        

    Mohamad H. Makhzoumi

     

     

                     *                        

    Scott D. Sandell

     

     

                     *                        

    Peter W. Sonsini

     

     

     

     

     

     

     

    */s/ Louis S. Citron           

    Louis S. Citron

    As attorney-in-fact

    This Agreement relating to Schedule 13D was executed by Louis S. Citron on behalf of the individuals listed above pursuant to a Power of Attorney a copy of which is attached hereto as Exhibit 2.

     

     

     

     

     

     

    CUSIP No. 81726A100

    13D Page 17 of 18 Pages    

    EXHIBIT 2

     

    POWER OF ATTORNEY

     

    KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Louis S. Citron, Timothy Schaller, Sasha Keough and Stephanie Brecher, and each of them, with full power to act without the others, his or her true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his or her capacity as a direct or indirect general partner, director, officer or manager of any partnership, corporation or limited liability company, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any and all regulations promulgated thereunder, and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he or she might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his or her substitutes, may lawfully do or cause to be done by virtue hereof.

     

    IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 13th day of March, 2017.

     

     

    /s/ M. James Barrett            

    M. James Barrett

     

    /s/ Peter J. Barris                

    Peter J. Barris

     

    /s/ Forest Baskett                

    Forest Baskett

     

    /s/ Ali Behbahani                 

    Ali Behbahani

     

    /s/ Colin Bryant                   

    Colin Bryant

     

    /s/ Carmen Chang               

    Carmen Chang

     

    /s/ Anthony A. Florence, Jr.

    Anthony A. Florence, Jr.

     

    /s/ Carol G. Gallagher          

    Carol G. Gallagher

     

    /s/ Dayna Grayson               

    Dayna Grayson

     

    /s/ Patrick J. Kerins             

    Patrick J. Kerins

     

    /s/ P. Justin Klein                

    P. Justin Klein

     

     

     

     

     

    CUSIP No. 81726A100

    13D Page 18 of 18 Pages    

     

     

     

     

    /s/ Vanessa Larco               

    Vanessa Larco

     

    /s/ Joshua Makower             

    Joshua Makower

     

    /s/ Mohamad H. Makhzoumi

    Mohamad H. Makhzoumi

     

    /s/ Edward T. Mathers         

    Edward T. Mathers

     

    /s/ David M. Mott                

    David M. Mott

     

    /s/ Sara M. Nayeem            

    Sara M. Nayeem

     

    /s/ Jason R. Nunn                

    Jason R. Nunn

     

    /s/ Gregory Papadopoulos    

    Gregory Papadopoulos

     

    /s/ Chetan Puttagunta          

    Chetan Puttagunta

     

    /s/ Jon Sakoda                     

    Jon Sakoda

     

    /s/ Scott D. Sandell              

    Scott D. Sandell

     

    /s/ A. Brooke Seawell          

    A. Brooke Seawell

     

    /s/ Peter W. Sonsini             

    Peter W. Sonsini

     

    /s/ Melissa Taunton             

    Melissa Taunton

     

    /s/ Frank M. Torti                

    Frank M. Torti

     

    /s/ Ravi Viswanathan           

    Ravi Viswanathan

     

    /s/ Paul E. Walker               

    Paul E. Walker

     

    /s/ Rick Yang                      

    Rick Yang

     

      

     

    Get the next $DYNS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DYNS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DYNS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Senti Bio Debuts as Publicly Traded Company Focused on Developing Next-Generation Cell and Gene Therapies Engineered with Gene Circuits

    - Business combination with Dynamics Special Purpose Corp. completed today; gross proceeds from transaction to Senti Bio expected to total approximately $156.5 million - - Combined company Senti Bio will be listed on the Nasdaq Global Market under ticker symbol "SNTI" - - IND filings for preclinical oncology candidates SENTI-202 and SENTI-301 anticipated in 2023 - SOUTH SAN FRANCISCO, Calif., June 09, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. ("Senti Bio"), a biotechnology company developing next-generation cell and gene therapies using its proprietary gene circuit platform, today announced the completion of its business combination with Dynamics Special Purpose Corp. (("D

    6/9/22 7:30:00 AM ET
    $DYNS

    Senti Bio to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. ("Senti Bio"), a leading Gene Circuit company today announced that Tim Lu, MD, PhD, Chief Executive Officer and Co-Founder, will present a corporate overview at the 40th Annual J.P. Morgan Virtual Healthcare Conference on Tuesday, January 11, 2022 at 2:00 p.m. EST. Senti Bio uses its Gene Circuit platform to program cell and gene therapies with potentially enhanced capabilities. Gene Circuits, which are created via synthetic biology and encoded as novel and proprietary combinations of DNA sequences, enable cells to sense inputs, compute decisions with biological logic, and respond to disease environment

    1/6/22 8:02:00 AM ET
    $DYNS

    Senti Bio and Dynamics Special Purpose Corp. Announce Business Combination Agreement to Create Publicly Listed Company Pioneering Gene Circuit-Engineered Cell and Gene Therapies

    - Business combination with Dynamics Special Purpose Corp. (NASDAQ:DYNS) is expected to provide more than $296 million in gross proceeds, over $153 million of which is fully committed in a common stock Private Investment in Public Equity ("PIPE") financing and from non-redemption agreements -  - Over $86 million in non-redemption agreements committed from existing Dynamics investors including funds managed by ARK Investment Management LLC, funds and accounts managed by Counterpoint Global (Morgan Stanley Investment Management), Invus, and T. Rowe Price funds - - Over $66 million in a PIPE financing committed from institutional investors including 8VC, Amgen Ventures, funds and accounts man

    12/20/21 7:05:00 AM ET
    $DYNS
    $ILMN
    $MRNA
    Medical Specialities
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: Laboratory Analytical Instruments

    $DYNS
    SEC Filings

    View All

    Dynamics Special Purpose Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Senti Biosciences, Inc. (0001854270) (Filer)

    1/9/23 7:54:29 AM ET
    $DYNS

    SEC Form 424B3 filed by Dynamics Special Purpose Corp.

    424B3 - Senti Biosciences, Inc. (0001854270) (Filer)

    12/12/22 8:23:31 AM ET
    $DYNS

    SEC Form 424B3 filed by Dynamics Special Purpose Corp.

    424B3 - Senti Biosciences, Inc. (0001854270) (Filer)

    12/12/22 8:20:56 AM ET
    $DYNS

    $DYNS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Knobelman Deborah was granted 30,000 shares

    4 - Senti Biosciences, Inc. (0001854270) (Issuer)

    10/4/22 4:47:13 PM ET
    $DYNS

    SEC Form 4 filed by Rajangam Kanya

    4 - Senti Biosciences, Inc. (0001854270) (Issuer)

    7/20/22 6:00:12 PM ET
    $DYNS

    SEC Form 4 filed by Mathers Edward T

    4 - Senti Biosciences, Inc. (0001854270) (Issuer)

    7/15/22 6:09:58 PM ET
    $DYNS

    $DYNS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Dynamics Special Purpose Corp.

    SC 13D - Senti Biosciences, Inc. (0001854270) (Subject)

    7/15/22 5:24:53 PM ET
    $DYNS

    SEC Form SC 13G/A filed by Dynamics Special Purpose Corp. (Amendment)

    SC 13G/A - Dynamics Special Purpose Corp. (0001854270) (Subject)

    4/5/22 11:21:36 AM ET
    $DYNS

    SEC Form SC 13G/A filed by Dynamics Special Purpose Corp. (Amendment)

    SC 13G/A - Dynamics Special Purpose Corp. (0001854270) (Subject)

    2/14/22 5:07:15 PM ET
    $DYNS